MedTrace Logo

MenPF-1 - A New Vaccine Against Meningococcal Disease

NCT01640652 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-12-07

No results posted yet for this study

Summary

In this study the investigators are testing a new vaccine against Neisseria meningitidis, the leading infective cause of childhood death in the UK. This bug (also known as meningococcus) can infect the lining of the brain (meningitis) or the blood stream (septicaemia) and can affect all ages, but especially children, adolescents and young adults.

The bug is classified into different groups based on its outer capsule (or shell), and this study will test a new vaccine to protect against group B meningococcus (MenB) disease, which is the most common type in the UK.

Vaccines are given to prepare the immune system to fight an infection. Vaccines work by stimulating the immune system to produce specialised proteins (called antibodies) and white blood cells designed to kill the bug later in life if needed.

Vaccines against other types of meningococcus have been developed and saved many lives. However MenB is different because its outer capsule does not stimulate the immune system very effectively. There is therefore no broadly effective vaccine against MenB disease.

Conditions

  • Serogroup B Meningococcal Disease

Interventions

BIOLOGICAL

MenPF-1.

A new vaccine against meningococcal disease.

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Norwegian Institute of Public Health

    collaborator OTHER_GOV

  • University of Oxford

    lead OTHER

Principal Investigators

  • Andrew J Pollard, PhD · Oxford Vaccine Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-07-31
Completion
2022-05-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01640652 on ClinicalTrials.gov